HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, J. Articles by Kumar, S. Search for Related Content PubMed PubMed Citation Articles by Smith, J. Articles by Kumar, S.

Antibody phage display technologies with special reference to angiogenesis

Julia Smith^*,1, Roland E. Kontermann, Jim Embleton^*, and Shant Kumar^*,

^* University of Manchester, Manchester, UK;
Vectron Therapeutics AG, Marburg, Germany; and
Christie Hospital NHS Trust, Manchester, UK

¹Correspondence: University of Manchester, Stopford Building, Oxford Rd, Manchester, M13 9PT, UK. E-mail: Jusmith{at}fs1.scg.man.ac.uk

The presence of blood vessels is a prerequisite for normal development, tissue growth, and tissue repair. However, its abnormal occurrence or absence can also potentiate disease processes. Angiogenic therapies have been used to stimulate blood vessel growth in ischemic conditions such as severe end-stage peripheral vascular disease, ischemic heart disease and stroke and for inhibition of angiogenesis in tumors. The targeting and identification of novel endothelial cell (EC) markers that can ultimately be used in angiogenic strategies is an expanding field but is limited by the availability of reagents. For instance repeated injection of mouse monoclonal antibodies (Mabs) against angiogenic EC, can result in the production of autoantibodies. Therefore, these mouse Mabs cannot be used for therapeutic purposes. Phage display technology was employed in this context to select antibodies, proteins, and peptides against known or novel EC antigens. Furthermore, technologies have been developed that enable the specific targeting of epitopes on cells including the endothelium with high-affinity/ avidity antibodies. The focus for these antibody targeting strategies are markers that are unique or up-regulated on angiogenic EC including the vascular endothelial growth factor receptor (VEGFR) KDR, endoglin (CD105), and the extracellular domain B (ED-B) domain of fibronectin (FN). These markers are reviewed herein.—Smith, J., Kontermann, R. E., Embleton, J., Kumar, S. Antibody phage display technologies with special reference to angiogenesis.

Key Words: vasculogenesis • angiogenic therapy • vascular targeting • VEGF • CD105

This article has been cited by other articles:

				V. L. T. Ballard, J. M. Holm, and J. M. Edelberg Quantitative PCR-based approach for rapid phage display analysis: a foundation for high throughput vascular proteomic profiling Physiol Genomics, September 14, 2006; 26(3): 202 - 208. [Abstract] [Full Text] [PDF]